Celgene's Intellectual Property Portfolio
Celgene has been aggressive in building and maintaining a deep and diverse intellectual property portfolio. The Company and its subsidiaries own or are licensees of over 800 pending patent applications/issued patents worldwide.
The patents and pending applications cover a wide variety of areas across multiple discovery and regulatory programs. Those areas include, but are not limited to, compositions of matter, polymorphs, intermediates, pharmaceutical compositions, diagnostics, methods of treatment, screening methodologies, and business methods.
In addition to pharmaceutical compositions and methods of use, Celgene has received valuable patents for its proprietary restricted distribution programs. These programs, commonly referred to under the S.T.E.P.S.® and RevAssist® marks, are designed as blueprints for delivering pharmaceutical products that offer life-saving or other important therapeutic benefits, but have potentially problematic side effects. These programs also serve as the basis for multiple international programs.
We believe that our sizeable intellectual property estate gives us an important global competitive advantage as we continue to develop and commercialize the IMiDs® compounds (Celgene's brand of immunomodulatory drugs), THALOMID® (thalidomide), and our deep pipeline of anti-inflammatory compounds, kinase inhibitors, ligase modulators, as well as placenta-derived and cord blood stem cells.
But we are not stopping here. We are continuing to expand our intellectual property portfolio as we add new compounds to our pipeline that relate to a variety of novel scientific targets and approaches.